icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
SfUGMtXGdZxu1Ps6